Sobi and Novimmune selected as Honourees for 2019 National Organization for Rare Disorders (NORD) Rare Impact Award in Industry Innovation for Gamifant® (emapalumab)
(WorldNews Sweden)

Sobi and Novimmune selected as Honourees for 2019 National Organization for Rare Disorders (NORD) Rare Impact Award in Industry Innovation for Gamifant® (emapalumab) Mon, 03/25/2019 - 08:30 Sobi and Novimmune selected as Honourees for 2019 National Organization for Rare Disorders (NORD) Rare Impact Award in Industry Innovation for Gamifant® (emapalumab) SobiTM and Novimmune SA have both been selected as honourees by the National Organization for Rare Disorders (NORD) for the 2019 Rare Impact Awards. The companies were nominated in the category of Industry Innovation in recognition of the US Food and Drug Administration (FDA) approval in November 2018 of Gamifant® (emapalumab-lzsg) for the...